Drug Profile
Tegoprazan - HK inno.N/RaQualia Pharma
Alternative Names: BLI-5100; CJ-12420; IN-A001; K-CAB; LXI-15028; RQ-00000004; RQ-4Latest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Developer CJ Cheiljedang Corp.; HK inno.N; RaQualia Pharma; Sebela Pharmaceuticals; Shandong Luoxin Pharmaceutical
- Class Amides; Anti-inflammatories; Antibacterials; Antiulcers; Benzimidazoles; Benzopyrans; Fluorobenzenes; Small molecules
- Mechanism of Action H(+) K(+)-exchanging ATPase inhibitors; Potassium-competitive acid blockers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Erosive oesophagitis; Gastro-oesophageal reflux
- Phase III Duodenal ulcer; Gastric ulcer; Helicobacter infections; Peptic ulcer
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Gastro-oesophageal-reflux in Japan (PO, Tablet)
- 11 Sep 2023 Registered for Gastro-oesophageal reflux in Peru (PO), prior to September 2023 (RaQualia Pharma pipeline, September 2023)
- 11 Sep 2023 Registered for Gastro-oesophageal reflux in Singapore (PO), prior to September 2023 (RaQualia Pharma pipeline, September 2023)